Thyroid Cancer Generalities

Rodrigo Arrangoiz MS, MD, FACS, FSSO
  • Cancers derived from thyroid follicular cells are classified into five main types:
    • Papillary thyroid carcinoma (PTC:
      • Representing 65% to 93% of all thyroid cancers worldwide
    • Follicular thyroid carcinoma (FTC):
      • 6% to 10% of cases
    • Oncocytic thyroid carcinoma (OC):
      • 3% to 7% of cases
    • Poorly differentiated thyroid carcinoma (PDTC):
      • 0.5% to 2%
    • Anaplastic thyroid carcinoma (ATC)
      • 1% of cases
  • PTC, FTC and OC:
    • Are generically termed differentiated thyroid carcinomas (DTCs):
      • Most patients present with localized disease and have a 5-year survival rates of greater than 98% by contrast to PDTC, which has a 5-year survival rate of 76%
  • The 2022 WHO classification of thyroid tumors:
    • Introduced a new intermediate clinical entity:
      • Differentiated high-grade thyroid carcinoma:
        • To define DTCs with a high mitotic rate and / or tumor necrosis:
          • As these have a 5-year survival rate comparable with that of PDTC
  • ATC is an extremely aggressive form of the disease:
    • Until recently, patients with ATC had a dismal median overall survival of 4 months:
      • Although this has improved markedly since 2018 with the FDA approval of new oncoprotein-targeted treatments coupled to evidence that immunotherapies may confer additional benefit
  • Thyroid parafollicular or C cells are a neuroendocrine lineage that gives rise to medullary thyroid cancers:
    • Which account for less than 5% of all thyroid cancers
#Arrangoiz #ThyroidSurgeon #HeadandNeckSurgeon #CancerSurgeon #SurgicalOncologist #MountSiniaMedicalCenter #MSMC #Miami #Mexico #EndocrineSurgery
Unknown's avatar

Published by Rodrigo Arrangoiz MS, MD, FACS, FSSO

My name is Rodrigo Arrangoiz I am a breast surgeon/ thyroid surgeon / parathyroid surgeon / head and neck surgeon / surgical oncologist that works at Center for Advanced Surgical Oncology in Miami, Florida. I was trained as a surgeon at Michigan State University from (2005 to 2010) where I was a chief resident in 2010. My surgical oncology and head and neck training was performed at the Fox Chase Cancer Center in Philadelphia from 2010 to 2012. At the same time I underwent a masters in science (Clinical research for health professionals) at the University of Drexel. Through the International Federation of Head and Neck Societies / Memorial Sloan Kettering Cancer Center I performed a two year head and neck surgery and oncology / endocrine fellowship that ended in 2016. Mi nombre es Rodrigo Arrangoiz, soy cirujano oncólogo / cirujano de tumores de cabeza y cuello / cirujano endocrino que trabaja Center for Advanced Surgical Oncology en Miami, Florida. Fui entrenado como cirujano en Michigan State University (2005 a 2010 ) donde fui jefe de residentes en 2010. Mi formación en oncología quirúrgica y e n tumores de cabeza y cuello se realizó en el Fox Chase Cancer Center en Filadelfia de 2010 a 2012. Al mismo tiempo, me sometí a una maestría en ciencias (investigación clínica para profesionales de la salud) en la Universidad de Drexel. A través de la Federación Internacional de Sociedades de Cabeza y Cuello / Memorial Sloan Kettering Cancer Center realicé una sub especialidad en cirugía de cabeza y cuello / cirugia endocrina de dos años que terminó en 2016.

Leave a comment